search
Back to results

IMPACT Intervention

Primary Purpose

Diabetes Mellitus, Type 2

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
IMPACT intervention
Sponsored by
Pole de Sante Chambery Nord
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring primary health care, patient-centered care, poverty areas, vulnerable populations, Glycated Hemoglobin A

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with type 2 diabetes
  • Inclusion HbA1c > 7.5%
  • Live in Hauts de Chambéry, Biollay or Renaudie district
  • Be able to give written consent

Exclusion Criteria:

  • Severe cognitive or psychological disorder that may affect study understanding
  • Pregnant or breastfeeding women
  • Had IMPACT intervention in the previous 24 months
  • Concurrent participation in another study
  • Concurrent participation in another diabetes educational care program
  • Life expectancy less than 6 months

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Intervention group

    Control group

    Arm Description

    IMPACT intervention

    Usual care

    Outcomes

    Primary Outcome Measures

    HbA1c
    Change in glycated haemoglobin (HbA1c)

    Secondary Outcome Measures

    HbA1c
    Change in glycated haemoglobin (HbA1c)
    Weight
    Change in weight
    Body mass index
    Change in body mass index
    Body fat mass (Bioelectrical impedance analysis)
    Change in body fat mass
    Body fat percentage (Bioelectrical impedance analysis)
    Change in body fat percentage
    Muscle mass (Bioelectrical impedance analysis)
    Change in muscle mass.
    Lipids - HDL cholesterol
    Change in HDL cholesterol
    Lipids - LDL cholesterol
    Change in LDL cholesterol
    Lipids - triglycerides
    Change in triglycerides

    Full Information

    First Posted
    October 27, 2020
    Last Updated
    November 1, 2020
    Sponsor
    Pole de Sante Chambery Nord
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04616053
    Brief Title
    IMPACT Intervention
    Official Title
    A Randomised Controlled Trial to Evaluate the Effectiveness of a Multidisciplinary Team Intervention on Glycaemic Control for Disadvantaged Type 2 Diabetes Patients in France.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2020
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2021 (Anticipated)
    Primary Completion Date
    September 2023 (Anticipated)
    Study Completion Date
    March 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Pole de Sante Chambery Nord

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Introduction : The prevalence of type 2 diabetes is increasing in France, especially in deprived districts. The Itineraires Medico-sociaux Programme d'Accompagnement sur un Territoire (IMPACT) intervention is intended for disadvantaged patients with a chronic disease (not only type 2 diabetes). The IMPACT intervention offers coordinated and patient-centered care by a multidisciplinary team with an empowerment approach. This personalised intervention lasts 6 months. This study aims to evaluate the effect of 6 months IMPACT intervention on glycaemic control (glycated haemoglobin - HbA1c) of patients with type 2 diabetes in deprived districts. Method : This will be a randomised, controlled, parallel group, multicenter, open-label trial. 140 adults with type 2 diabetes will be randomised in two arms : IMPACT intervention group (n : 70) and usual care group (n : 70). The primary outcome is change in glycated haemoglobin (HbA1c) from baseline to 6 months. The primary outcome will be analysed using a linear mixed effects model.
    Detailed Description
    This will be a randomised, controlled, parallel group, multicenter, open-label trial. Patients will be recruited among patients with type 2 diabetes referred to the IMPACT intervention. 144 patients will be randomised in two arms : IMPACT intervention group (n : 72) and usual care group (n : 72). IMPACT intervention : a referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program. The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patients with his health administrative procedures. Patients will have 3 visits. First visit (inclusion visit) : investigator collects baseline characteristics (sociodemographic data, comorbidity, treatment, diabetes complications, weight, height, body mass index, impedancemetry, HbA1c, lipids, creatinine, albuminuria/creatinuria ratio). Then the patient will be randomised. Second visit (midpoint visit) : investigator collects weight, BMI, impedancemetry, HbA1c and adverse events Third visit (end point visit) : investigator collects weight, BMI, impedancemetry, HbA1c, lipids and adverse events. Analysis : The primary outcome is change in glycated haemoglobin (HbA1c) from baseline to 6 months. The primary outcome will be analysed using a linear mixed effects model. Study groups, districts, time, group-time interaction and district-group interaction will be included as fixed effects. The model will include patients as a random effect. Sub-group analysis will be made with baseline HbA1c, sex, age, Epices score (French precarity score) and diabetes duration. The robustness of the model will be tested by replacing missing data with multiple imputation methods. The same statistical modelling approach will be used for the secondary outcomes.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetes Mellitus, Type 2
    Keywords
    primary health care, patient-centered care, poverty areas, vulnerable populations, Glycated Hemoglobin A

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    140 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Intervention group
    Arm Type
    Experimental
    Arm Description
    IMPACT intervention
    Arm Title
    Control group
    Arm Type
    No Intervention
    Arm Description
    Usual care
    Intervention Type
    Behavioral
    Intervention Name(s)
    IMPACT intervention
    Intervention Description
    A referent is assigned to the patient. A referent is a health worker (nurse, nutritionist, psychologist …). Patient builds with his referent a free care program (without condition or limit). The patient can choose individual consultation (for example : nutrition, tabacology, psychology …) and/or collective care (for example : patient education, physical activity, relaxation …). A community health worker can help patient with his health administrative procedures. This intervention lasts 6 months.
    Primary Outcome Measure Information:
    Title
    HbA1c
    Description
    Change in glycated haemoglobin (HbA1c)
    Time Frame
    From baseline to 6 months
    Secondary Outcome Measure Information:
    Title
    HbA1c
    Description
    Change in glycated haemoglobin (HbA1c)
    Time Frame
    From baseline to 3 months
    Title
    Weight
    Description
    Change in weight
    Time Frame
    At Months 3 and 6 from baseline
    Title
    Body mass index
    Description
    Change in body mass index
    Time Frame
    At Months 3 and 6 from baseline
    Title
    Body fat mass (Bioelectrical impedance analysis)
    Description
    Change in body fat mass
    Time Frame
    At Months 3 and 6 from baseline
    Title
    Body fat percentage (Bioelectrical impedance analysis)
    Description
    Change in body fat percentage
    Time Frame
    At Months 3 and 6 from baseline
    Title
    Muscle mass (Bioelectrical impedance analysis)
    Description
    Change in muscle mass.
    Time Frame
    At Months 3 and 6 from baseline
    Title
    Lipids - HDL cholesterol
    Description
    Change in HDL cholesterol
    Time Frame
    From baseline to 6 months
    Title
    Lipids - LDL cholesterol
    Description
    Change in LDL cholesterol
    Time Frame
    From baseline to 6 months
    Title
    Lipids - triglycerides
    Description
    Change in triglycerides
    Time Frame
    From baseline to 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with type 2 diabetes Inclusion HbA1c > 7.5% Live in Hauts de Chambéry, Biollay or Renaudie district Be able to give written consent Exclusion Criteria: Severe cognitive or psychological disorder that may affect study understanding Pregnant or breastfeeding women Had IMPACT intervention in the previous 24 months Concurrent participation in another study Concurrent participation in another diabetes educational care program Life expectancy less than 6 months
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Donatien Talon, Resident
    Phone
    +33679230064
    Email
    donatien.talon@gmail.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    22683130
    Citation
    Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012 Jun 16;379(9833):2252-61. doi: 10.1016/S0140-6736(12)60480-2. Epub 2012 Jun 9.
    Results Reference
    background
    PubMed Identifier
    25188210
    Citation
    Attridge M, Creamer J, Ramsden M, Cannings-John R, Hawthorne K. Culturally appropriate health education for people in ethnic minority groups with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2014 Sep 4;(9):CD006424. doi: 10.1002/14651858.CD006424.pub3.
    Results Reference
    background
    PubMed Identifier
    30552277
    Citation
    Captieux M, Pearce G, Parke HL, Epiphaniou E, Wild S, Taylor SJC, Pinnock H. Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews. BMJ Open. 2018 Dec 14;8(12):e024262. doi: 10.1136/bmjopen-2018-024262.
    Results Reference
    background

    Learn more about this trial

    IMPACT Intervention

    We'll reach out to this number within 24 hrs